Literature DB >> 25199695

Usefulness of sugammadex in a patient with Becker muscular dystrophy and dilated cardiomyopathy.

Tsukasa Shimauchi1, Ken Yamaura2, Sayaka Sugibe1, Sumio Hoka1.   

Abstract

A 54-year-old patient with Becker muscular dystrophy and dilated cardiomyopathy underwent laparoscopic cholecystectomy under total intravenous anesthesia. Muscle relaxation was induced by rocuronium (0.4 mg/kg body weight) under train-of-four (TOF) ratio monitoring. The TOF ratio was 0 at intubation, and 0.2 at the end of surgery. Residual muscle relaxant activity was successfully reversed by sugammadex (2 mg/kg body weight) without any hemodynamic adverse effects (TOF ratio 1.0 at extubation). The clinical and hemodynamic findings suggest that sugammadex can be safely used in patients with Becker muscular dystrophy and dilated cardiomyopathy.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  cardiomyopathy, dilated; gamma-cyclodextrins: sugammadex; myotonic dystrophy: Becker

Mesh:

Substances:

Year:  2014        PMID: 25199695     DOI: 10.1016/j.aat.2014.02.005

Source DB:  PubMed          Journal:  Acta Anaesthesiol Taiwan


  3 in total

1.  The ultrasound-guided nerve blocks of abdominal wall contributed to anesthetic management of cholecystectomy in a patient with Becker muscular dystrophy without using muscle relaxants.

Authors:  Masato Iwata; Naoya Kuzumoto; Yuka Akasaki; Masayo Morioka; Kana Nakayama; Nobuyoshi Matsuzawa; Katsuhiro Kimoto; Toshiyuki Shimomura
Journal:  JA Clin Rep       Date:  2017-12-08

2.  Anesthesia for patients with PTRF mutations: a case report.

Authors:  Atsuko Hirano; Tomohiko Takada; Mariko Senda; Hidemasa Takahashi; Takeo Suzuki
Journal:  JA Clin Rep       Date:  2018-01-25

3.  Use of sugammadex in patients with neuromuscular disorders: a systematic review of case reports.

Authors:  Usha Gurunathan; Shakeel Meeran Kunju; Lisa May Lin Stanton
Journal:  BMC Anesthesiol       Date:  2019-11-19       Impact factor: 2.217

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.